Research Analysts Issue Forecasts for Imunon Q1 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Research analysts at Brookline Capital Markets issued their Q1 2027 earnings per share estimates for Imunon in a report released on Friday, June 5th. Brookline Capital Markets analyst K. Dolliver expects that the company will post earnings of ($0.81) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($3.69) per share. Brookline Capital Markets also issued estimates for Imunon’s Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.78) EPS and Q4 2027 earnings at ($0.75) EPS.

Imunon (NASDAQ:IMNN) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38.

IMNN has been the topic of several other reports. Maxim Group set a $10.00 price target on Imunon and gave the company a “buy” rating in a research note on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.00.

Imunon Stock Down 2.4%

Shares of IMNN opened at $2.01 on Tuesday. Imunon has a 12-month low of $1.96 and a 12-month high of $27.65. The firm has a market capitalization of $8.44 million, a price-to-earnings ratio of -0.39 and a beta of 1.95. The stock’s 50-day moving average price is $2.67 and its 200 day moving average price is $3.20.

Institutional Investors Weigh In On Imunon

Several large investors have recently modified their holdings of the stock. DRW Securities LLC grew its stake in shares of Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after purchasing an additional 3,803 shares during the period. Riverview Capital Advisers LLC grew its position in Imunon by 193.3% during the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after acquiring an additional 22,649 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Imunon during the 4th quarter worth approximately $1,017,000. 4.47% of the stock is currently owned by institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.